Omega Pharma Innovation & Development NV v Market Australia, Inc

In the Federal Court of Australia, Justice Condon considered a dispute between Omega Pharma Innovation & Development NV (the applicant) and Market Australia, Inc (the respondent). The applicant sought to prevent the respondent from using the trade mark "OMEGAPRO" in relation to a range of pharmaceutical and health-related products. The applicant alleged that the respondent's use of this mark infringed its registered trade mark "OMEGA-3" and constituted misleading and deceptive conduct under the *Australian Consumer Law*.

The central legal issues before the Court were whether the respondent's trade mark "OMEGAPRO" was deceptively similar to the applicant's registered trade mark "OMEGA-3" for the purposes of trade mark infringement, and whether the respondent's conduct in using "OMEGAPRO" was likely to mislead or deceive consumers as to the origin or nature of its products, thereby contravening the *Australian Consumer Law*.

Justice Condon's reasoning focused on the application of established principles for assessing deceptive similarity and misleading or deceptive conduct. The Court considered the visual, aural, and conceptual similarities between the two marks, taking into account the goods in respect of which they were used. The Court also examined the overall impression created by the marks on the relevant class of consumers. Applying these principles, the Court found that there was a sufficient degree of similarity between the marks, particularly given the shared prefix "OMEGA" and the nature of the goods, to give rise to a likelihood of confusion. Furthermore, the Court determined that the respondent's use of "OMEGAPRO" was likely to mislead or deceive consumers into believing that the respondent's products were associated with or endorsed by the applicant.

Consequently, Justice Condon ordered that the respondent be restrained from using the trade mark "OMEGAPRO" in relation to the specified goods and that the respondent pay the applicant's costs.